KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $7.5 billion.

  • Vertex Pharmaceuticals' Total Liabilities rose 1413.46% to $7.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 billion, marking a year-over-year increase of 1413.46%. This contributed to the annual value of $6.1 billion for FY2024, which is 1890.95% up from last year.
  • As of Q3 2025, Vertex Pharmaceuticals' Total Liabilities stood at $7.5 billion, which was up 1413.46% from $6.9 billion recorded in Q2 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Total Liabilities peaked at $7.5 billion during Q3 2025, and registered a low of $3.0 billion during Q2 2021.
  • Over the past 5 years, Vertex Pharmaceuticals' median Total Liabilities value was $4.9 billion (recorded in 2023), while the average stood at $4.8 billion.
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Total Liabilities plummeted by 252.9% in 2021, and later skyrocketed by 4179.18% in 2023.
  • Over the past 5 years, Vertex Pharmaceuticals' Total Liabilities (Quarter) stood at $3.3 billion in 2021, then rose by 27.18% to $4.2 billion in 2022, then grew by 21.51% to $5.1 billion in 2023, then rose by 18.91% to $6.1 billion in 2024, then increased by 23.19% to $7.5 billion in 2025.
  • Its Total Liabilities stands at $7.5 billion for Q3 2025, versus $6.9 billion for Q2 2025 and $6.4 billion for Q1 2025.